Skye Bioscience Inc (SKYE)

$4.25 -0.01 (-0.23%)
Market Cap 131.70M
Revenue (ttm) 0.00
Net Income (ttm) -26.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 242,400
Avg Vol 386,564
Day's Range N/A - N/A
Shares Out 30.99M
Stochastic %K 91%
Beta 2.34
Analysts Strong Sell
Price Target $15.71

Company Profile

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in Jan...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 410 0266
Address:
11250 El Camino Real, Suite 100, San Diego, United States
AnomalyDetective
AnomalyDetective Sep. 13 at 1:01 PM
New Week 38 MDA breakout picks out for members with additional highlighted bonus breakout stocks: https://seekingalpha.com/mp/1201-value-momentum-breakouts/articles/6203878-september-mda-breakout-stocks-week-38-and-highlighted-top-gainers Top gainers last week $LDI $SKYE $REAL contributed to +33% peak gains and simulated +225% YTD returns in average cumulative weekly returns through 37 weeks. Extending the weekly count to 337 weeks with at least one pick gaining over 10% in less than a week. Last week delivered 3/4 stocks over 10% in the most positive week of Q3 selections.
0 · Reply
Multipliers
Multipliers Sep. 13 at 10:13 AM
$SKYE I like the new tagline: Ninmacinab, it's a no-brainer!
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 13 at 3:51 AM
Enter: $SKYE OCT 17 2025 $5 CALLS Buy in Price: $0.95 - $1.25 Take Profit: $1.14 Stop Bleeding: $0.84 ROI Potential: 20% Exit Within: 75 Minutes https://moneygroup.us/alerts
0 · Reply
nirahl
nirahl Sep. 12 at 11:34 PM
$SKYE New "Why nimacimab is different" LinkedIn post from Skye Bioscience: https://www.linkedin.com/posts/skyebioscience_why-is-nimacimab-different-activity-7372351443892101120-kYPd
1 · Reply
DanishViking92
DanishViking92 Sep. 12 at 10:12 AM
$SKYE ..so much manipulation, up and down 20-30 penny every day..
2 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 12 at 4:26 AM
Enter: $SKYE OCT 17 2025 $5 CALLS Buy in Price: $0.95 - $1.25 Take Profit: $1.15 Stop Bleeding: $0.84 ROI Potential: 21% Exit Within: 26 Minutes https://moneygroup.us/alerts
0 · Reply
theiciestofmattz
theiciestofmattz Sep. 11 at 9:44 PM
$SKYE Alright Phase 2 Data, daddy needs a new pair of shoes
1 · Reply
DanishViking92
DanishViking92 Sep. 11 at 6:42 PM
$SKYE I have a sell order at $40 -know what you hold
0 · Reply
Rascal7777777
Rascal7777777 Sep. 11 at 6:34 PM
$SKYE I think I need 30 now to breakeven
0 · Reply
Theflash88
Theflash88 Sep. 11 at 5:38 PM
$SKYE Adding on dips..
0 · Reply
Latest News on SKYE
Skye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 9:45 AM EDT - 4 days ago

Skye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

Sep 5, 2025, 1:35 PM EDT - 9 days ago

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

Skye Bioscience, Inc. (SKYE) Virtual KOL Event Transcript

Sep 5, 2025, 1:30 AM EDT - 9 days ago

Skye Bioscience, Inc. (SKYE) Virtual KOL Event Transcript

Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

Sep 4, 2025, 7:00 AM EDT - 10 days ago

Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

Sep 2, 2025, 7:00 AM EDT - 12 days ago

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

Aug 27, 2025, 7:00 AM EDT - 18 days ago

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

Aug 21, 2025, 7:00 AM EDT - 24 days ago

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 8:36 PM EDT - 5 weeks ago

Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

Aug 7, 2025, 4:01 PM EDT - 5 weeks ago

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

Jul 30, 2025, 7:00 AM EDT - 6 weeks ago

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing

Jul 7, 2025, 11:59 PM EDT - 2 months ago

Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

Jun 23, 2025, 7:00 AM EDT - 2 months ago

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions

Jun 17, 2025, 7:00 AM EDT - 3 months ago

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions

Skye Bioscience to Participate in Upcoming Investment Conferences

May 22, 2025, 7:00 AM EDT - 4 months ago

Skye Bioscience to Participate in Upcoming Investment Conferences

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

May 19, 2025, 5:00 AM EDT - 4 months ago

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 13, 2025, 4:05 PM EDT - 4 months ago

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity

May 13, 2025, 7:00 AM EDT - 4 months ago

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity

Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript

May 9, 2025, 7:20 PM EDT - 4 months ago

Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity

May 8, 2025, 4:01 PM EDT - 4 months ago

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity

Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025

May 7, 2025, 7:00 AM EDT - 4 months ago

Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025

Skye Bioscience to Participate in May Investment and Medical Conferences

Apr 29, 2025, 7:00 AM EDT - 4 months ago

Skye Bioscience to Participate in May Investment and Medical Conferences

A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value

Apr 16, 2025, 7:50 AM EDT - 5 months ago

A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value

Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models

Apr 15, 2025, 3:42 PM EDT - 5 months ago

Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models

LLY

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model

Apr 15, 2025, 7:00 AM EDT - 5 months ago

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model

Skye Bioscience to Conduct Meetings at Piper Sandler Conference

Apr 14, 2025, 7:00 AM EDT - 5 months ago

Skye Bioscience to Conduct Meetings at Piper Sandler Conference

Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 9:58 PM EDT - 6 months ago

Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript

Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025

Mar 14, 2025, 7:00 AM EDT - 6 months ago

Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025

Skye Bioscience to Present at TD Cowen Health Care Conference

Feb 20, 2025, 7:00 AM EST - 7 months ago

Skye Bioscience to Present at TD Cowen Health Care Conference

Skye Bioscience Announces Participation in February Conferences

Feb 4, 2025, 7:00 AM EST - 7 months ago

Skye Bioscience Announces Participation in February Conferences

MoneyShow's Best Investment Ideas For 2025: Part 8

Feb 3, 2025, 9:20 AM EST - 7 months ago

MoneyShow's Best Investment Ideas For 2025: Part 8

DELL FNV MNKD MSTR SKE AMSC

Skye Bioscience to Present at J.P. Morgan Healthcare Conference

Dec 19, 2024, 7:00 AM EST - 9 months ago

Skye Bioscience to Present at J.P. Morgan Healthcare Conference

Skye Bioscience: Nimacimab Targets Safer Weight Loss, Speculative Buy

Dec 10, 2024, 8:32 AM EST - 9 months ago

Skye Bioscience: Nimacimab Targets Safer Weight Loss, Speculative Buy

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

Nov 14, 2024, 7:00 AM EST - 10 months ago

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

Skye Bioscience, Inc. (SKYE) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 10:36 PM EST - 11 months ago

Skye Bioscience, Inc. (SKYE) Q3 2024 Earnings Call Transcript

Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights

Nov 7, 2024, 4:01 PM EST - 11 months ago

Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights

Skye Bioscience to Announce Third Quarter 2024 Results

Nov 1, 2024, 7:00 AM EDT - 11 months ago

Skye Bioscience to Announce Third Quarter 2024 Results

Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences

Oct 21, 2024, 7:00 AM EDT - 11 months ago

Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences

3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore

Oct 9, 2024, 1:13 PM EDT - 1 year ago

3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore

RENT SCWO

Skye: Moving Weight Loss Drugs To The Next Level

Sep 4, 2024, 11:26 AM EDT - 1 year ago

Skye: Moving Weight Loss Drugs To The Next Level

Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences

Aug 26, 2024, 7:00 AM EDT - 1 year ago

Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences

Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity

Aug 22, 2024, 7:00 AM EDT - 1 year ago

Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity

Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Aug 21, 2024, 10:00 AM EDT - 1 year ago

Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Investors With Losses In Skye Bioscience Inc Are Urged To Join Fraud Investigation With The Schall Law Firm

Aug 19, 2024, 11:00 AM EDT - 1 year ago

Investors With Losses In Skye Bioscience Inc Are Urged To Join Fraud Investigation With The Schall Law Firm

Skye Bioscience Inc Shareholders Encouraged Be A Part Of Fraud Investigation With The Schall Law Firm

Aug 18, 2024, 11:00 AM EDT - 1 year ago

Skye Bioscience Inc Shareholders Encouraged Be A Part Of Fraud Investigation With The Schall Law Firm

Skye Bioscience Inc Investors Invited To Partake In Fraud Investigation With The Schall Law Firm

Aug 17, 2024, 11:00 AM EDT - 1 year ago

Skye Bioscience Inc Investors Invited To Partake In Fraud Investigation With The Schall Law Firm

Skye Bioscience Inc Shareholders Encouraged To Join In Fraud Investigation With The Schall Law Firm

Aug 16, 2024, 11:00 AM EDT - 1 year ago

Skye Bioscience Inc Shareholders Encouraged To Join In Fraud Investigation With The Schall Law Firm

Skye Bioscience Inc Investors Encouraged To Join In Fraud Investigation With The Schall Law Firm

Aug 15, 2024, 11:00 AM EDT - 1 year ago

Skye Bioscience Inc Investors Encouraged To Join In Fraud Investigation With The Schall Law Firm

Skye Bioscience Inc Investors Urged To Participate In Fraud Investigation With The Schall Law Firm

Aug 14, 2024, 10:30 PM EDT - 1 year ago

Skye Bioscience Inc Investors Urged To Participate In Fraud Investigation With The Schall Law Firm

Skye Bioscience Inc Investors Encouraged To Join Fraud Investigation With The Schall Law Firm

Aug 14, 2024, 12:40 AM EDT - 1 year ago

Skye Bioscience Inc Investors Encouraged To Join Fraud Investigation With The Schall Law Firm

Skye Bioscience Inc Investors Urged To Join The Fraud Investigation With The Schall Law Firm

Aug 13, 2024, 2:00 AM EDT - 1 year ago

Skye Bioscience Inc Investors Urged To Join The Fraud Investigation With The Schall Law Firm

AnomalyDetective
AnomalyDetective Sep. 13 at 1:01 PM
New Week 38 MDA breakout picks out for members with additional highlighted bonus breakout stocks: https://seekingalpha.com/mp/1201-value-momentum-breakouts/articles/6203878-september-mda-breakout-stocks-week-38-and-highlighted-top-gainers Top gainers last week $LDI $SKYE $REAL contributed to +33% peak gains and simulated +225% YTD returns in average cumulative weekly returns through 37 weeks. Extending the weekly count to 337 weeks with at least one pick gaining over 10% in less than a week. Last week delivered 3/4 stocks over 10% in the most positive week of Q3 selections.
0 · Reply
Multipliers
Multipliers Sep. 13 at 10:13 AM
$SKYE I like the new tagline: Ninmacinab, it's a no-brainer!
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 13 at 3:51 AM
Enter: $SKYE OCT 17 2025 $5 CALLS Buy in Price: $0.95 - $1.25 Take Profit: $1.14 Stop Bleeding: $0.84 ROI Potential: 20% Exit Within: 75 Minutes https://moneygroup.us/alerts
0 · Reply
nirahl
nirahl Sep. 12 at 11:34 PM
$SKYE New "Why nimacimab is different" LinkedIn post from Skye Bioscience: https://www.linkedin.com/posts/skyebioscience_why-is-nimacimab-different-activity-7372351443892101120-kYPd
1 · Reply
DanishViking92
DanishViking92 Sep. 12 at 10:12 AM
$SKYE ..so much manipulation, up and down 20-30 penny every day..
2 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 12 at 4:26 AM
Enter: $SKYE OCT 17 2025 $5 CALLS Buy in Price: $0.95 - $1.25 Take Profit: $1.15 Stop Bleeding: $0.84 ROI Potential: 21% Exit Within: 26 Minutes https://moneygroup.us/alerts
0 · Reply
theiciestofmattz
theiciestofmattz Sep. 11 at 9:44 PM
$SKYE Alright Phase 2 Data, daddy needs a new pair of shoes
1 · Reply
DanishViking92
DanishViking92 Sep. 11 at 6:42 PM
$SKYE I have a sell order at $40 -know what you hold
0 · Reply
Rascal7777777
Rascal7777777 Sep. 11 at 6:34 PM
$SKYE I think I need 30 now to breakeven
0 · Reply
Theflash88
Theflash88 Sep. 11 at 5:38 PM
$SKYE Adding on dips..
0 · Reply
DanishViking92
DanishViking92 Sep. 11 at 2:18 PM
$SKYE Heavy resistance at $4.30.. Cmon lets push through!! $$
1 · Reply
BIOTECH_GURU
BIOTECH_GURU Sep. 11 at 1:50 PM
$SKYE run mf run🚀🚀🔥🚀🚀🚀🚀
0 · Reply
leis5
leis5 Sep. 11 at 10:55 AM
https://www.unicef.org/reports/feeding-profit For the firdt time in history more fat kids than skinny kids in the world $SKYE
1 · Reply
MissionaryTrader
MissionaryTrader Sep. 10 at 10:16 PM
$SKYE
4 · Reply
J_THunder77
J_THunder77 Sep. 10 at 5:10 PM
$SKYE The most important I see is that Nimacimab is a unique molecule. It doesnt have to pass the blood brain barrier to stop hunger. There is nothing on the market that does that. Also it can used for other metabolic disorders as well. The tolerabilty and safety profile are what will push this over the top. The study of combining it with Wegovy was an excellent idea. Essentially this drug could rescue people on current GLP-1’s and make it safer to take over a longer period of time. It sounds like Nimacimab can not only be taken more safely in combination with the weight loss drugs on the market it can be used for other metabolic disorders. So the big pharma companies would definitely be interested in buying this company imo. Combining this safe profile with a drug like Wegovy spells a recipe for cornering the market on weight loss.
1 · Reply
Epafroditus
Epafroditus Sep. 10 at 4:56 PM
$SKYE
1 · Reply
YazzJr
YazzJr Sep. 10 at 3:35 PM
$SKYE Here is the transcript for the recent KOL. It's really interesting. Take a look and tell me what you guys think. https://seekingalpha.com/article/4819835-skye-bioscience-inc-skye-virtual-kol-event-transcript
1 · Reply
BIOTECH_GURU
BIOTECH_GURU Sep. 10 at 3:35 PM
$SKYE built a nice base, now will start the march towards $10.
0 · Reply
nirahl
nirahl Sep. 10 at 3:16 PM
$SKYE Webcast recording available for today's Morgan Stanley Global Healthcare Conference Fireside Chat today: https://ir.skyebioscience.com/company-information/ir-calendar-webcasts/detail/20250910-morgan-stanley-global-healthcare-conference-fireside-chat
0 · Reply
DanishViking92
DanishViking92 Sep. 10 at 2:51 PM
$SKYE
0 · Reply
DanishViking92
DanishViking92 Sep. 10 at 2:50 PM
$SKYE $5 this week and next week we go much much higher! Especially looking forward to the conference in Vienna next Thursday - Title: A multiple dose study to evaluate the safety and tolerability of nimacimab, a peripherally restricted, inhibitory CB1 receptor antibody in subjects with metabolic associated fatty liver disease (MAFLD)
0 · Reply
RDMoneylover
RDMoneylover Sep. 10 at 2:41 PM
$LIXT Lets go to $10 $SKYE $IBIO
0 · Reply